ElendiLabs — Regulatory consultancy platform connecting medical device and pharmaceutical manufacturers with verified experts worldwide
All regulatory hubs
Regulatory hub

Overview of the Danish Medicines Agency (Lægemiddelstyrelsen) and Medical Device Regulation

An overview of the Danish Medicines Agency's role in supervising medical devices, managing clinical trials, and ensuring patient safety in Denmark.

Overview

Summary of this regulator or jurisdiction and how it relates to market access.

Official regulator site

Danish Medicines Agency (Lægemiddelstyrelsen) Overview

The Danish Medicines Agency (DKMA) is an agency under the Danish Ministry of Interior and Health. It is the central authority responsible for the legislation and supervision of medical devices in Denmark, ensuring they are safe, effective, and of high quality.

Key Roles and Responsibilities:

  • Regulatory Supervision: Administers Danish and EU legislation, specifically the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR).
  • Clinical Investigations: Evaluates and authorizes applications for clinical trials of medical devices and performance studies for IVDs.
  • Market Surveillance: Monitors devices already on the market through inspections of manufacturers and distributors.
  • Vigilance (Materiovigilance): Receives and analyzes incident reports from companies, healthcare professionals, and citizens to prevent recurrences.
  • Notified Bodies: Supervises the bodies responsible for certifying medical devices (CE marking).
  • Registration: Manages the registration of Danish manufacturers, importers, and authorized representatives.
  • Advice: Provides regulatory guidance to startups, SMEs, and researchers.

The Agency works closely with other EU member states to harmonize standards and improve health safety across Europe.

Articles & guides

Insight articles mapped to this region on ElendiLabs.

Other

February 10, 2026

Performance Studies for In Vitro Diagnostic Medical Devices in Denmark

Denmark regulates performance studies for IVDs under IVDR, requiring authorisation for studies with invasive procedures or risks, and notification for certain CE-marked or companion diagnostic studies using left-over samples.

Read article

Other

February 9, 2026

Certificates of Free Sale for Medical Devices in Denmark

The Danish Medicines Agency issues Certificates of Free Sale for CE-marked medical devices and IVDs intended for export outside the EEA, to Danish-based manufacturers or authorised representatives, with a fee of DKK 1,362 per certificate.

Read article

Other

February 9, 2026

Notified Bodies for Medical Devices: Role and Oversight in Denmark

Notified bodies assess conformity for higher-risk medical devices under EU MDR/IVDR; in Denmark, the Medicines Agency supervises but no local bodies are designated—manufacturers select from EU-wide NANDO list.

Read article

Other

February 9, 2026

Danish Medicines Agency Regulatory Advice for Medical Device Companies

The Danish Medicines Agency offers free regulatory advice meetings for startups, SMEs, and research units on EU MDR/IVDR requirements, including CE marking and clinical investigations, but excludes device classification and approvals.

Read article

Clinical Trials

February 7, 2026

Notification Requirements for Post-Market Clinical Follow-Up Investigations in Denmark

In Denmark, PMCF investigations involving additional invasive or burdensome procedures require notification to the Danish Medicines Agency 30 days before commencement, along with ethics committee approval.

Read article

Clinical Trials

February 7, 2026

Application Process for Clinical Investigations of Medical Devices in Denmark

Applications for clinical investigations in Denmark are submitted via email to the Danish Medicines Agency and ethics committees while EUDAMED is delayed, requiring specific documents like protocols and Danish-language participant information.

Read article

Other

February 7, 2026

Danish Medicines Agency FAQ on Artificial Intelligence in Medical Devices

The Danish Medicines Agency provides guidance on AI in medical devices, covering qualification, classification, conformity assessment, clinical evaluation, and challenges with continuous learning systems under EU MDR.

Read article

Clinical Trials

February 6, 2026

Assessment Process for Clinical Investigations of Medical Devices in Denmark

The Danish Medicines Agency assesses clinical investigation applications in a validation phase (up to 15 days) followed by a 45-day assessment phase, with possible suspensions for additional information, focusing on safety, ethics, and specific requirements like contraception for certain devices.

Read article

Clinical Trials

February 6, 2026

Clinical Investigations of Medical Devices in Denmark

Denmark requires notification to the Danish Medicines Agency and ethics committee approval for clinical investigations of medical devices under EU MDR, with specific rules for applications, substantial modifications, and performance studies for IVDs.

Read article

Other

February 6, 2026

Derogation from CE Marking for Medical Devices in Denmark

Denmark allows derogation from CE marking for specific medical devices without conformity assessment under exceptional circumstances to protect public health or patient safety, requiring application with healthcare professional justification.

Read article

Other

February 6, 2026

Danish Medicines Agency Guidance for Medical Device Development

The Danish Medicines Agency provides practical guidance for manufacturers developing medical devices, covering classification, conformity assessment, clinical evaluation, quality management, and post-market surveillance under EU MDR.

Read article

Other

February 6, 2026

Extension of EU IVDR Transitional Provisions for In Vitro Diagnostic Medical Devices

The EU extended IVDR transitional provisions to address implementation challenges, allowing legacy IVDs to remain on the market until 2025-2027 depending on risk class, while in-house devices gain phased compliance extensions to ensure continued availability and patient safety.

Read article

Clinical Trials

February 5, 2026

Completion Requirements for Clinical Investigations of Medical Devices in Denmark

In Denmark, sponsors must notify the Danish Medicines Agency upon completion of clinical investigations, submit final reports within specified timelines, and ensure public availability of reports, with special rules for early termination.

Read article

Other

February 5, 2026

Language Requirements for Medical Devices in Denmark

In Denmark, labelling and instructions for use of medical devices must generally be in Danish when made available to end users or patients, with possible exemptions granted by the Danish Medicines Agency for specific cases.

Read article

Other

February 5, 2026

CE Marking Process for Medical Devices in the EU and Denmark

CE marking certifies that a medical device complies with EU safety and performance requirements under MDR and IVDR, enabling free marketing across the EU, with manufacturers responsible for the process and higher-risk devices requiring notified body certification.

Read article

Registration

February 4, 2026

Regulatory Framework and Guidance for Medical Devices in Denmark

Denmark implements EU medical device regulations through MDR and IVDR, supplemented by national acts and executive orders, with guidance from MDCG documents and harmonised standards covering classification, conformity assessment, clinical investigations, and market surveillance.

Read article

Clinical Trials

February 4, 2026

Fees for Clinical Investigations of Medical Devices in Denmark

The Danish Medicines Agency does not charge fees for applications, notifications, or substantial modifications related to clinical investigations of medical devices.

Read article

Clinical Trials

February 4, 2026

Notification Requirements for Clinical Investigations of Medical Devices in Denmark

In Denmark, sponsors must notify the Danish Medicines Agency for certain clinical investigations under MDR Articles 62, 74(1), and 82, with simultaneous ethics committee submission for some types and specific timelines.

Read article

Registration

February 4, 2026

Registration and Marketing of Medical Devices in Denmark

In Denmark, medical devices must comply with EU MDR/IVDR and national rules to be marketed, with manufacturers responsible for CE marking, risk analysis, conformity assessment, market surveillance, and incident reporting—no prior authority approval required.

Read article

Registration

February 3, 2026

Danish Medicines Agency Regulation of Medical Devices

The Danish Medicines Agency oversees medical devices in Denmark, ensuring EU compliance through CE marking, handling vigilance reports, clinical investigations, supply interruptions, and providing guidance to manufacturers, professionals, and citizens.

Read article

Medical Advertisements

February 2, 2026

Advertising Rules for Medical Devices in Denmark

In Denmark, advertising of medical devices must be adequate, objective, and verifiable, aligned with the device's intended purpose, with specific rules on financial benefits and supervision by the Danish Medicines Agency under executive order no. 715 of 2022.

Read article

Other

February 2, 2026

Key Changes to IVD Regulation in Denmark under EU IVDR

The EU In Vitro Diagnostic Medical Devices Regulation (IVDR) applied from May 2022 introduces risk-based classification, increased notified body involvement, stricter performance evaluation requirements, and transitional provisions to ensure continued access to safe IVDs in Denmark.

Read article

Post Market Surveillance

February 2, 2026

Incident Reporting for Medical Devices in Denmark

In Denmark, manufacturers, healthcare professionals, and citizens must or may report serious incidents involving medical devices to the Danish Medicines Agency, enabling investigation and potential corrective actions to ensure patient safety.

Read article

Clinical Trials

February 1, 2026

Authorisation Process for Substantial Modifications in Clinical Investigations in Denmark

In Denmark, substantial modifications to authorised clinical investigations require prior authorisation from the Danish Medicines Agency, with ethics committee assessment, submitted via email with updated documents showing changes.

Read article